Launch of the Cancer Dashboard for Italy

How good is access to cancer medicines in Italy, and what can other European countries learn from it? A new dashboard-style report provides an in-depth analysis of Italy’s access to innovative cancer medicines, focusing on the Fund for Innovative Drugs (Fondo per i Farmaci Innovativi).

The report reveals that Italy performs well in a European context, demonstrating that Italy has the third high reimbursement rate for new cancer medicines approved by the European Medicines Agency (EMA). Italy also achieves shorter times to reimbursement decision after EMA approval than many other European countries. Central to this achievement is the Fund for Innovative Drugs, established in 2017 to improve access to innovative treatments. Based on the input from three leading Italian healthcare experts (Francesco Perrone, Emanuele Monti, Anna Maria Mancuso), the report summarizes the numerous benefits of the Fund. It also includes recommendations to optimize the Fund’s effectiveness.

The launch of the dashboard-report was marked by a public presentation at the conference “Inventing for Lung: The Role of Innovation in Treating Lung Cancer ” on December 3, 2024 in Rome, Italy.

Title: Cancer Dashboard for Italy – Access to Cancer Medicines
Presenter: Thomas Hofmarcher
Conference: Inventing for Lung: The Role of Innovation in Treating Lung Cancer
Place: Rome, Italy
Date: December 3, 2024

For more information, please contact Thomas Hofmarcher

Cancer Dashboard for Italy – Access to Cancer Medicines, IHE 2024, Lund, Sweden